All Resources
Our resource hub to discover reports, policy papers and other forms of informative content
Cost Drivers Report 2024: Analysis of Private Drug Plan Trends in Canada
For the second year in a row,
we saw considerable growth
in the number of claimants
with an 8.5% increase, making
it the main driver of overall
cost. This increase in claimants
was balanced by a low single
digit increase in the cost per
claimants of 2.7%. Read the full report.
The Canadian Research and Development Pharmaceutical Sector, 2021
This study examines the contribution of the Canadian research and development (R&D) pharmaceutical sector on the Canadian economy in 2021. […]
Clinical Trials Research Note
In many areas of high unmet patient need, early access to new medicines through clinical trials are the only option for Canadian patients. There are over 3,000 ongoing clinical trials in Canada which provide significant value to patients. Early access to innovative treatments improves health outcomes, increases quality of life, and gives hope to patients and their loved ones. Clinical trials also provide value to our healthcare system, research ecosystem, and economy.
Cost Drivers Report 2023
Annual cost growth in Canada’s private drug benefit market is driven by increased utilization and chronic disease drugs, with an increase in claimants post‑pandemic.
Read the full report.
Value of Medicines in Canada
This study examines and quantifies the value of innovative treatments in Canada to patient lives, the healthcare system and to society. Case studies include: HPV vaccines, Melanoma treatments, treatment for Rheumatoid Arthritis and Hepatitis C.
Cost of A Private Drug Plan Claim
IMC contracted Reformulary Group to analyze the cost of a private plan prescription drug claim in Canada, and separately in Quebec. This report summarizes that analysis.
Developing a Canadian managed entry approach for new innovation: What can Canada learn from Europe?
Many new therapies coming to the market are not well served by the traditional drug reimbursement approaches currently employed by Canada’s public plans. A growing number of European regulatory authorities have been using novel managed entry agreements (MEA) and innovative access agreements (IAA) to accelerate approval times and improve availability to patients.
Clinical Trials in Canada
The innovative pharmaceutical industry has sponsored over two-thirds of clinical trials initiated in Canada in the last 5 years and contributed over $15 billion to the Canadian economy annually.
Innovative Access Arrangements and Managed Entry
A growing number of payers in many countries are looking to managed entry agreements (MEAs) and other innovative access arrangements (IAAs) to allow rapid access to medicines that address significant unmet needs.
